Its efficacy and tolerability in cancer therapy was first demonstrated in ALK-positive non-small cell lung cancer (NSCLC) [81,82,83,84,85], ultimately leading to its approval by the Food and Drug Administration for use in NSCLC in 2013. The gene discussed is ALK; the disease is cancer.